<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115219</url>
  </required_header>
  <id_info>
    <org_study_id>20040275</org_study_id>
    <nct_id>NCT00115219</nct_id>
  </id_info>
  <brief_title>Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)</brief_title>
  <official_title>A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study objective will be to evaluate the efficacy and safety of etanercept
      50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept (50 mg
      QW) and concomitant methotrexate therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving a good or moderate DAS28 response (as defined by the EULAR28 response criteria) at Week 12</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve American College of Rheumatology (ACR) 20, 50, and 70 responses at Weeks 12 and 24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a good or moderate DAS28 response (as defined by the EULAR28 response criteria at Week 24 and the proportion achieving clinical remission (DAS28&lt;2.6) at Weeks 12 and 24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline with respect to the DAS28 score and ACR score (including HAQ) criteria at Weeks 12 and 24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in patient-reported outcomes as measured by the SF-36 at Weeks 12 and 24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of etanercept 50mg BIW responders at Week 12 who mantain a clinical improvement with etanercept 50mg QW (defined as no DAS28 increase of greater than 0.6 from Week 12) at Week 24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (SAEs and AEs) in three study periods (4-week open label run-in period, 12-week double blinded period A, and 12-week open-label period B)</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Rheumatoid Arthritis

          -  RA with a disease duration &gt; 6 months

          -  Current and prior but continuous etanercept (50 mg weekly) treatment for at least 5
             months prior to screening

          -  Subjects must be receiving methotrexate (MTX) at a stable dose &gt; 15 mg/week at least 4
             weeks prior to screening

          -  Sub-optimal response to etanercept defined by the presence of the following criteria
             (based on 28 joint count) at screening: 5 or more swollen joints and 5 or more tender
             joints

          -  Subjects who are currently receiving oral corticosteroids must be on a dose equivalent
             to prednisone less than or equal to 10 mg/day at screening

          -  Subjects who are currently receiving non-steroidal anti-inflammatory drugs (NSAIDs),
             must be on a stable dose for at least 2 weeks prior to screening

          -  Subjects who are currently receiving DMARD therapy (including sulfasalazine,
             hydroxy-chloroquine and leflunomide), must be on a stable dose for at least 4 weeks
             prior to screening

        Exclusion Criteria:

          -  Nursing mothers, female subjects planning on becoming pregnant, or male subjects
             planning a pregnancy with their spouse/partner while in the study

          -  ACR functional class IV

          -  Receipt of any investigational drug or biologic within 4 weeks of study drug
             initiation

          -  Concurrent or history of psychiatric disease that would interfere with ability to
             comply with study protocol or give informed consent

          -  History of alcohol or drug abuse within 12 months of screening visit

          -  Severe comorbidities including: History of cancer (other than resected cutaneous basal
             and squamous cell carcinoma, and in situ cervical cancer) within 5 years of screening
             visit. Documentation of disease-free state since treatment required; Diagnosis of
             Class III or IV congestive heart failure (CHF) or myocardial infarction (MI) within 12
             months of screening; Unstable or stable angina pectoris; Uncontrolled hypertension
             (defined as systolic blood pressure measurement of greater than 180 mm Hg or a
             diastolic blood pressure of greater than 110 mm Hg); Oxygen-dependent pulmonary
             disease; Known HIV-positive status or other immunodeficiency syndromes; Chronic
             hepatitis B (HbsAg) or C (HCV); Systemic lupus erythematosus (SLE); CNS demyelinating
             events suggestive of multiple sclerosis; Presence of active infection or any
             underlying diseases that could predispose subjects to infection (e.g., history of
             recurrent infections, non-healing leg ulcers, advanced or poorly controlled diabetes);
             Active or prior history of tuberculosis (or known exposure).

          -  Concurrent treatment with cyclophosphamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.enbrel.com</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, Furst DE. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 2008 Jul;58(7):1921-30. doi: 10.1002/art.23493.</citation>
    <PMID>18576334</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2005</study_first_submitted>
  <study_first_submitted_qc>June 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2005</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis, RA</keyword>
  <keyword>EnbrelÂ® (etanercept)</keyword>
  <keyword>Clinical Trials, Amgen</keyword>
  <keyword>Immunex, Methotrexate (MTX)</keyword>
  <keyword>Rheumatoid Arthritis (RA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

